Interactions between galectin-3 and cardiovascular risk in patients with chronic lymphocytic leukemia in remission: results of 3-year prospective study


  • B. B. Samura Zaporizhzhia State Medical University, Ukraine,



galectin-3, chronic lymphocytic leukemia, cardiovascular events, risk factors


Purpose – to evaluate interactions between the value of circulating galectin-3 and cardiovascular risk in patients with chronic lymphocytic leukemia in remission.

Materials and methods. One hundred fifty seven out subjects with chronic lymphocytic leukemia in full or partial remission were enrolled in the study. Observation period was up to 12 months. Blood samples for biomarkers measurements were collected at the visit of inclusion into the study. ELISA method for measurements of circulating level of galectin-3 was used. Cardiovascular events were evaluated for 3 year observation period.

Results. Two hundred seventy cumulative clinical events occurred in 68 patients (43.3 %) within the follow-up, with their distribution being as follows: 12 deaths for cardiovascular reasons, 17 life-threatening arrhythmias, 36 cardiac ischemic events, 9 strokes, 38 decompensated chronic heart failures and 58 hospital admissions for cardiovascular reasons.

Mean levels of galectin-3 in free-events subject cohort and subjects cohort with cardiovascular events were 5.22 ± 3.06 ng/ml and 12.64 ± 5.24 ng/ml (Р < 0.0001). In patients after antitumor treatment with anthracyclines mean levels of galectin-3 were higher in comparing with patients after antitumor treatment without anthracyclines (Р = 0.0014). There were no differences in the value of galectin-3 in depend on gender, age, cumulative dose of anthracyclines, arterial hypertension, hyperlipidemia, diabetes mellitus, body mass index, smoking.

Conclusions. Among patients with chronic lymphocytic leukemia in remission increased circulating galectin-3 associates with presence of anthracyclines in antitumor treatment and increased cumulative cardiovascular events within 3 year observation period.



Kriachok, I. A. (2013) Khronicheskij limfolejkoz: novoe v lechenii. Podhody k terapii pervoj linii i ikh e'volyuciya [Chronic lymphocytic leukemia: new in treatment Approaches to the first-line treatment and their evolution]. Klinicheskaya onkologiya, 3, 121–129. [in Russian].

Samura, B. B., Kolesnik, Y. M., & Syvolap, V. V. (2014) Znachennia tsyrkuliuiuchoho halektynu-3 v prohnozuvannі kardіovaskuliarnykh podіi u patsіientіv іz khronіchnoiu lіmfotsytarnoiu leikemіieiu v remіsіi [Value of circulating galectin-3 for prognosis of cardiovascular events in patients with chronic lymphocytic leukemia in remission]. Zaporozhye medical journal, 6(86), 44–47. [in Ukrainian]. doi:

Armstrong, G. T., Oeffinger, K. C., Chen, Y., Kawashima, T., Yasui, Y., Leisenring, W., et al. (2013) Modifiable risk factors and major cardiac events among adult survivors of childhood cancer. J. Clin. Oncol., 31(29), 3673–3680. doi: 10.1200/JCO.2013.49.3205.

Dumic, J., Dabelic, S., & Flögel, M. (2006) Galectin-3: an open-ended story. Biochim Biophys Acta., 1760(4), 616–35. doi: 10.1016/j.bbagen.2005.12.020.

Ewer, M. S., & Ewer, S. M. (2015) Cardiotoxicity of anticancer treatments. Nat Rev Cardiol., 12(9), 547–58. doi: 10.1038/nrcardio.2015.65.

FDA.510(k) Substantial equivalence determination decision summary. Review memorandum K093758. Retrieved from

Sano, H., Hsu, D. K., Apgar, J. R., Yu, L., Sharma, B. B., Kuwabara, I., et al. (2003) Critical role of galectin-3 in phagocytosis by macrophages. J Clin Invest., 112(3), 389–97. doi: 10.1172/JCI17592.

How to Cite

Samura BB. Interactions between galectin-3 and cardiovascular risk in patients with chronic lymphocytic leukemia in remission: results of 3-year prospective study. Current issues in pharmacy and medicine: science and practice [Internet]. 2018Oct.24 [cited 2024Jun.16];(3). Available from:



Original research